Franklin Biotechnology Discovery Fund Class R6 (FRBRX)

203.13
Net Asset Value
+0.88%
1 Day
+18.40%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
0.63%
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. It predominantly invests in equity securities, primarily common stock. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of foreign or U.S. issuer. It is non-diversified.

Performance

1 month-1.41% 3 years--
3 months+12.62% 5 years--
1 year+63.92% Since inception+47.01%
Data through --

Peer Comparisonvs. Health

 FRBRXCategory
Performance 5-yr return--+22.35%
Expense ratio0.63%1.44%
Risk 5 year sharpe ratio1.461.49
Net assets$2.0B$3.9B
Average market cap$10.9B$35.3B
Average P/E33.425.2
Portfolio turnover49%49%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyFranklin Templeton Investments
Fund manager & tenureEvan McCulloch / 17 Years
Minimal initial investment$1,000,000.00
Minimum IRA investment--

Holdings

U.S. stock89.23%
International stock4.75%
Cash4.44%
Fixed income1.58%
Other0.00%
Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
CELG Celgene9.79%
BIIB Biogen7.25%
GILD Gilead Sciences6.50%
AMGN Amgen5.20%
MDVN Medivation Inc3.42%
REGN Regeneron Pharmaceuticals3.15%
ILMN Illumina Inc2.96%
BMRN Biomarin Pharmaceutical Inc2.94%
INCY Incyte Corp2.87%
ALXN Alexion Pharmaceuticals Inc2.43%

To view my watchlist

Not a member yet?

Sign up now for a free account